CUE News and Press, Cue Biopharma Inc.

Primary endpoint and the key secondary endpoint were met with high statistical significance and CUE-221 demonstrated an overall favorable safety profile Clinically different efficacy profile observed relative to XOLAIR ® (omalizumab) highlights potential for a fundamental mechanism-based b...

BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company targeting transformative therapies for immune-mediated diseases, today announced the appointment of James M. Ahlers as Chief Financial Officer. Mr. Ahlers will report to Preside...

BOSTON, July 13, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company targeting transformative therapies for immune-mediated diseases, today announced the appointment of Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research &am...

2026-07-10 15:05:30 ET Investment thesis Cue Biopharma, Inc. (CUE) trades at an enterprise value of $86 million which rests on a single in-licensed Phase 2 anti-IgE antibody, CUE-221, that is neither owned not controlled by Cue. The China readout will be generated by the licenso...

A look at the top 10 most actives in the United States Zhibao Technology Inc. (ZBAO) rose 47.4% to $0.43625 on volume of 191,062,211 shares T3 Defense Inc. (DFNS) fell 19.7% to $0.118 on volume of 140,059,194 shares Direxion Daily Semiconductor Bear 3X (SOXS) rose 4.0% to $4.2314 on volume ...

2026-07-10 04:08:47 ET Cue Biopharma ( CUE ) has entered into a definitive securities purchase agreement to raise approximately $50.0M in gross proceeds through a private placement with a group of accredited institutional investors.... Read the full article on Seeking ...

BOSTON, July 09, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical stage biopharmaceutical company focused on developing transformative therapies targeting functional cures for immunological disorders, today announced that it has entered into a securities purchase agreement w...

2026-06-09 05:18:04 ET More on biotechnology stocks: Tango Therapeutics, Inc. (TNGX) Discusses Promising Clinical Results for Vopimetostat and Pan-RAS Inhibitor Combination in MTAP-Deleted Pancreatic Cancer Transcript Tango Therapeutics, Inc. (TNGX) Discusses Promising C...

Daniel Camardo, former CEO and executive commercial leader with a track record of successful launches joins the board Viola Meehan, former CFO with broad experience in governance, strategic finance and executive leadership joins the board  BOSTON, June 02, 2026 (GLOBE NEWSWIRE) -- Cu...

BOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc.  (Nasdaq: CUE), a clinical-stage therapeutics company focused on developing transformative therapies targeting functional cures for immunological disorders, today announced that Shao-Lee Lin, president and chief executive officer,...